PBYI MEXC RealStocks
Own real PBYI shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 08:31:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
PUMA BIOTECHNOLOGY INC. (PBYI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.24, with a market capitalization of $369.13M and a P/E ratio of 15.49. Over the past 52 weeks, its price has ranged from $4.80 to $11.50. This page covers its latest market performance, valuation, price trends and company information.
$369.13M | |
$7.15 | |
$7.64 | |
$6.62 | |
$7.14 | |
344.47K | |
377.79K | |
15.49 | |
$11.50 | |
$4.80 | |
-- | |
2026-09-30 |
PUMA BIOTECHNOLOGY INC. (PBYI) last closed at $7.24 as of 2026-11-19 00:31:00, up 1.26% ($0.09) from the previous close of $7.14.
During the latest regular trading session, PBYI traded between $6.62 and $7.64, with a volume of 344.47K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, PUMA BIOTECHNOLOGY INC. (PBYI) moved from $8.14 to $7.24, representing a decline of 11.04% ($0.90).
The stock traded between $6.62 and $8.56 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 492.76 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 36.5%
PBYI is currently trading at $7.24, placing it 36.5% of the way from its 52-week low of $4.80 to its 52-week high of $11.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 179 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PUMA BIOTECHNOLOGY INC. (PBYI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PBYI, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PBYI shares and USD.
PBYI Shares to USD
1.00 PBYI shares = 7.241 USD
Calculations are estimates based on the latest available price and are for reference only.